

Analyst

John Hester 612 8224 2871
Tanushree Jain 612 8224 2849

Authorisation

TS Lim 612 8224 2810

Kazia Therapeutics

Strength To Strength

Recommendation

Buy (unchanged)

Price

\$1.03

Valuation

\$1.50 (previously \$1.00)

Risk

Speculative

GICS Sector

Pharmaceuticals & Biotechnology

Expected Return

| | |
|-----------------------|-------|
| Capital growth | 45.6% |
| Dividend yield | 0 |
| Total expected return | 45.6% |

Company Data & Ratios

| | |
|------------------------|-----------------|
| Enterprise value | \$89.4m |
| Market cap | \$87.4m |
| Issued capital | 94.6m |
| Free float | 100% |
| Avg. daily val. (52wk) | \$162,000 |
| 12 month price range | \$0.34 - \$1.24 |

Price Performance

| | (1m) | (3m) | (12m) |
|----------------|-------|--------|--------|
| Price (A\$) | 0.56 | 0.38 | 0.37 |
| Absolute (%) | 76.00 | 160.53 | 167.57 |
| Rel market (%) | 75.54 | 150.29 | 173.33 |

Absolute Price



SOURCE: IRESS

FY20 Result Summary

Kazia released its FY20 result and annual report earlier today. The company spent \$9.5m in on clinical trials in FY20 for the development of its two drug candidates and reported a net loss for the year of \$12.4m. Cash as at 30 June 2020 was \$8.7m providing the company with sufficient funding until early 2021.

The pipeline of news flow in relation to the development of paxalisib over the next few months appears full. The key items are 1) final results from the 30 patient phase II trial in glioblastoma 2) interim results from the phase I clinical trial in DIPG at St Jude Children's Research Hospital 3) Interim results from the phase II clinical trial in HER2+ brain metastases at Dana-Farber Cancer, and finally 4) recruitment to the GBM AGILE pivotal study is expected to commence later this calendar year. KZA also expects to report final results from the phase I trial of Cantrixil in ovarian cancer.

The annual report provided updated data in regard to pricing of paxalisib should it reach commercialisation. In the US during 2018, the median cost of a newly approved cancer drug was US\$148,000 per year of treatment – nearly double the selling price assumed in our financial model. The ultimate price achieved by the drug is determined by amongst other things its effect size and health economics data. The company estimates global market for Glioblastoma (not including DIPG or other brain metastases) at US\$1.5bn. Based on this data we have revised upward our selling price estimate for paxalisib. The model retains a significant discount to reflect the inherent risk in clinical trials. This upgrade to selling price is the key driver of the lift in valuation.

Retain Buy (Speculative), Valuation raised to \$1.50

We retain our Buy rating. Valuation is raised to \$1.50. The contractual arrangement for GBM AGILE remains under negotiation, including the company's funding requirement. The financial model assumes the company raises further equity to fund its obligation, however, this is likely to be one of several options available should the next set of data from the phase II GBM trial be consistent with the earlier interim data.

Earnings Forecast

| June Year End | FY20 | FY21e | FY22e | FY23e |
|-----------------------|-------|-------|-------|-------|
| Revenues | 1.0 | 4.3 | 7.2 | 44.0 |
| EBIT \$m | -12.7 | -19.7 | -18.8 | 16.0 |
| NPAT (underlying) \$m | -12.4 | -19.8 | -18.9 | 15.9 |
| NPAT (reported) \$m | -12.4 | -19.8 | -18.9 | 15.9 |
| EPS underlying (cps) | -17.0 | -12.5 | -11.9 | 10.0 |
| EPS growth % | nm | nm | nm | nm |
| PER (x) | nm | nm | nm | 10.3 |
| FCF yield (%) | nm | nm | nm | nm |
| EV/EBITDA (x) | nm | nm | nm | nm |
| Dividend (cps) | - | - | - | 10.00 |
| Franking | 0% | 0% | 0% | 100% |
| Yield % | 0% | 0% | 0% | 971% |
| ROE % | -88% | -75% | -259% | 131% |

SOURCE: BELL POTTER SECURITIES ESTIMATES

Regulatory Concessions

In recent weeks KZA has made a series of encouraging announcements regarding regulatory concessions with the FDA. These concessions are designed to accelerate the regulatory approval of promising new drugs through the agency.

7 Aug – paxalisib awarded rare pediatric disease designation (RPDD) by the FDA for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG).

DIPG is a rare form of brain cancer in children, of which there are approximately 300 cases per year in the US. The disease is fatal in all cases with median survival less than 1 year.

With RPDD granted, Kazia may now be eligible to receive a 'rare pediatric disease priority review voucher' (PRV) if paxalisib is approved for DIPG.

A PRV grants the holder an expedited six-month review of a new drug application by the FDA. PRVs can be sold to other companies and have historically commanded prices between US\$68 million and US\$350 million.

We expect interim data from the DIPG study being conducted at St Jude's Children's Research Hospital (Memphis) in 2H CY2020. St Jude's is a leading hospital in the US for the treatment of childhood cancers. Encouraging data is likely to warrant further clinical studies.

20 Aug – paxalisib granted fast track GBM. Key advantages include enhanced access to the FDA throughout the development process, eligibility to apply for accelerated approval and priority review at the time of an NDA submission.

24 Aug – paxalisib granted orphan drug designation (ODD) for the treatment of malignant glioma which includes DIPG. ODD can provide drug developers with up to seven years of Orphan Drug Exclusivity (ODE), extending the effective life of a commercial product. It also provides opportunities for grant funding, protocol assistance, and financial benefits, such as a waiver of New Drug Application fees, and tax credits.

Figure 1 - Summary of clinical trial program

| | Indication | Stage | n | Progress | Design | Sponsor | Registration |
|-----------|----------------------------------|-----------|-----------|------------------------|---|--|--------------|
| paxalisib | Glioblastoma | Phase II | 27 | Completed recruitment | Single Arm, open label | Kazia Therapeutics | NCT03522298 |
| | Glioblastoma | Phase III | up to 200 | Ethics approvals | Randomised Controlled Study | Kazia Therapeutics/GBM Agile | NCT03970447 |
| | Brain metastases - any source | Phase II | 150 | Recruiting | Three treatment cohorts. Pts receive one of three drugs, one of which is Paxalisib. | Alliance for clinical trials in Oncology and Genentech | NCT03994796 |
| | Brain metastases - breast cancer | Phase II | 47 | Recruiting | Non randomised, single arm, combination study of Paxalisib with Trastuzumab | Dana Farber Cancer Institute | NCT03765983 |
| | DIPG (childhood brain cancer) | Phase II | 41 | Active, Not Recruiting | Various treatment cohorts on paxalisib and radiation therapy | St Jude Children's Research Hospital | NCT03696355 |
| Cantrixil | Brain Metastases - any source | Phase 1 | 36 | Recruiting | 3+3 dose escalation cohorts on paxalisib and radiation therapy | Memorial Sloan Kettering | NCT04192981 |
| | Recurrent Ovarian Cancer | Phase 1 | 28 | Completed recruitment | Part A - dose escalation, Part B Expansion Cohort | Kazia Therapeutics | NCT02903771 |

SOURCE: COMPANY DATA AND BELL POTTER SECURITIES ESTIMATES

Risk Areas

The key risk include but are not limited to the follow items:

Kazia's ability to achieve profitability is dependent on a number of factors, including its ability to complete successful clinical trials, obtain regulatory approval for its products and successfully commercialise or partner both Paxalisib and Cantrixil. There is no guarantee that the company will achieve these goals.

Kazia does not currently generate revenue from product sales and revenues are not anticipated in the short to medium term. The company is likely to continue to rely on shareholders to fund the business of the foreseeable future.

Clinical trial risk

KZA may be unable to secure necessary approvals from regulatory agencies and institutional bodies (clinics and hospitals) to conduct future clinical trials. There is also no assurance that either of the drugs under development will prove to be safe and efficacious in clinical trials, or that the regulatory approval to manufacture and market its products will be received. Clinical trials might also potentially expose the Company to product liability claims in the event its products in development have unexpected effects on clinical subjects.

Paxalisib and Cantrixil must both undergo a comprehensive and highly regulated development and review process before receiving approval for marketing.

The company is also dependent on commercially attractive markets remaining available to it during the commercialisation phase and there is a risk that, once developed and ready for sale, commercial sales to fund sufficient revenues for continued operations and growth, may not be achieved.

Arrangements with third-party collaborators

Kazia may pursue collaborative arrangements with pharmaceutical and life science companies, academic institutions or other partners to complete the development and commercialisation of its products (including for the GBM Agile study). These collaborators may be asked to assist with funding or performing clinical trials, manufacturing, regulatory approvals or product marketing. There is no assurance that Kazia will attract and retain appropriate strategic partners or that any such collaborators will perform and meet commercialisation goals. If Kazia is unable to find a partner, it would be required to develop and commercialise its products at its own expense. This may place significant demands on the Company's internal resources and potentially delay the commercialisation.

Requirement to raise additional funds

The company may be required to raise additional equity or debt capital in the future. There is no assurance that it will be able to raise that capital when it is required or, even if available, the terms may be unsatisfactory. If the company is unsuccessful in obtaining funds when they are required, it may need to delay or scale down its operations.

Intellectual property

The company's ability to leverage its innovation and expertise depends upon its ability to protect its intellectual property and any improvements to it. The intellectual property may not be capable of being legally protected, it may be the subject of unauthorised disclosure or be unlawfully infringed, or the company may incur substantial costs in asserting or defending its intellectual property rights.

Kazia Therapeutics

as at 27 August 2020

Recommendation

Buy, Speculative

Price

\$1.03

Valuation

\$1.50

Table 1 - Financial summary

| | FY19 | FY20 | FY21e | FY22e | FY23e | Valuation Ratios (A\$m) | FY19 | FY20 | FY21e | FY22e | FY23e |
|-------------------------------|---------------|---------------|---------------|---------------|--------------|----------------------------|-------------|-------------|--------------|--------------|-------------|
| Year Ending June | | | | | | Reported EPS (cps) | -16.6 | -17.0 | -12.3 | -11.9 | 10.0 |
| R&D incentive | 1.4 | 1.0 | 4.3 | 7.2 | 7.2 | Normalised EPS (cps) | -16.6 | -17.0 | -12.3 | -11.9 | 10.0 |
| Total Revenue | 1.5 | 1.0 | 4.3 | 7.2 | 44.0 | EPS growth (%) | nm | nm | nm | nm | nm |
| COGS | - | - | - | - | - | | | | | | |
| Gross profit | 1.5 | 1.0 | 4.3 | 7.2 | 44.0 | | | | | | |
| | | | | | | PE(x) | nm | nm | nm | nm | 10.3 |
| Expenses Net of R&D | -6.5 | -9.5 | -16.0 | -16.0 | -16.0 | EV/EBIT (x) | nm | nm | nm | nm | nm |
| Other expenses | -3.9 | -3.2 | -8.0 | -10.0 | -12.0 | | | | | | |
| Total Expenses | -12.2 | -13.7 | -24.0 | -26.0 | -28.0 | P/NTA (x) | 91.4 | 57.3 | 11.6 | 34.0 | - |
| EBIT | -10.7 | -12.7 | -19.7 | -18.8 | 16.0 | Book Value Per Share (cps) | 22.9 | 14.9 | 16.7 | 4.8 | 14.8 |
| Interest income | 0.0 | 0.0 | 0.2 | -0.1 | -0.1 | Price/Book (x) | 4.5 | 6.9 | 6.2 | 21.5 | 7.0 |
| Pre tax profit | (10.6) | (12.7) | (19.5) | (18.9) | 15.9 | | | | | | |
| Tax expense | 0.3 | 0.3 | - | - | - | DPS (cps) | - | - | - | - | - |
| NPAT- normalised | (10.3) | (12.4) | (19.5) | (18.9) | 15.9 | Payout ratio % | 0% | 0% | 0% | 0% | 0% |
| Reported NPAT | (10.3) | (12.4) | (19.5) | (18.9) | 15.9 | Dividend Yield % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| | | | | | | Franking % | 0% | 0% | 0% | 0% | 0% |
| | | | | | | FCF yield % | nm | nm | nm | nm | nm |
| Cashflow (A\$m) | FY19 | FY20 | FY21e | FY22e | FY23e | Net debt/Equity | 0% | 0% | 0% | 0% | 0% |
| Gross cashflow | -6.7 | -8.8 | -19.6 | -18.7 | 16.1 | Net debt/Assets | 0% | 0% | 0% | 0% | 0% |
| Net interest | 0.0 | 0.0 | 0.2 | -0.1 | -0.1 | Gearing | net cash | net cash | net cash | net cash | net cash |
| Operating cash flow | -6.7 | -8.8 | -19.4 | -18.8 | 16.0 | Net debt/EBITDA (x) | n/a | n/a | n/a | n/a | n/a |
| Proceeds from asset sales | 2.4 | 0.0 | 0.0 | 0.0 | 0.0 | Interest cover (x) | n/a | n/a | n/a | n/a | n/a |
| Free cash flow | -4.3 | -8.8 | -19.4 | -18.8 | 16.0 | | | | | | |
| Business acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | |
| Proceeds from issuance | 3.8 | 12.1 | 32.0 | 0.0 | 0.0 | | | | | | |
| Movement in borrowings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | |
| Other | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | |
| Change in cash held | -0.5 | 3.3 | 12.6 | -18.8 | 16.0 | | | | | | |
| Cash at beginning of period | 6.0 | 5.4 | 8.7 | 21.3 | 2.5 | | | | | | |
| FX adjustment | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | |
| Cash at year end | 5.4 | 8.7 | 21.3 | 2.5 | 18.4 | | | | | | |
| | | | | | | | | | | | |
| Balance Sheet (A\$m) | FY19 | FY20 | FY21e | FY22e | FY23e | | | | | | |
| Cash | 5.4 | 8.7 | 21.3 | 2.5 | 18.4 | Interim Results | 1H20 | 2H20 | 1H21e | 2H21e | |
| Receivables | 1.7 | 1.4 | 1.4 | 1.4 | 1.4 | Revenues | 0.6 | 0.4 | 0.6 | 3.7 | |
| Other current assets | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | R&D Expense | -4.2 | -5.3 | 0.0 | 0.0 | |
| Property, Plant and Equipment | - | - | - | - | - | All Other expenses | -2.4 | -0.8 | -4.0 | -4.0 | |
| Intangibles | 13.5 | 12.4 | 12.4 | 12.4 | 12.4 | EBIT | -6.2 | -6.5 | -7.4 | -12.3 | |
| Other non current assets | 0.2 | - | - | - | - | | | | | | |
| Total assets | 21.2 | 23.0 | 35.5 | 16.7 | 32.7 | | | | | | |
| Trade payables | 1.8 | 3.5 | 3.5 | 3.5 | 3.5 | | | | | | |
| Other liabilities | 1.4 | 1.8 | 1.9 | 2.0 | 2.1 | | | | | | |
| Deferred taxes | 3.7 | 3.4 | 3.4 | 3.4 | 3.4 | | | | | | |
| Provisions | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | | | | | | |
| Total Liabilities | 7.0 | 8.9 | 9.0 | 9.1 | 9.2 | | | | | | |
| Net Assets | 14.2 | 14.1 | 26.5 | 7.6 | 23.5 | | | | | | |
| Share capital | 36.6 | 48.8 | 80.8 | 80.8 | 80.8 | | | | | | |
| Other equity | 2.5 | 1.5 | 1.4 | 1.4 | 1.4 | | | | | | |
| Retained earnings | (24.9) | (36.2) | (55.7) | (74.6) | (58.7) | | | | | | |
| Reserves | - | - | - | - | - | | | | | | |
| Shareholders Equity | 14.2 | 14.1 | 26.5 | 7.6 | 23.5 | | | | | | |

SOURCE: BELL POTTER SECURITIES ESTIMATES

Recommendation structure

Buy: Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

Hold: Expect total return between -5% and 15% on a 12 month view

Sell: Expect <-5% total return on a 12 month view

Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.

Such investments may carry an exceptionally high level of capital risk and volatility of returns.

Research Team

| Staff Member | Title/Sector | Phone | @bellpotter.com.au |
|-------------------|--------------------------------|-----------------|--------------------|
| TS Lim | Head of Research/Banks | 612 8224 2810 | tslim |
| Analysts | | | |
| Lafitani Sotiriou | Diversified Financials/Fintech | 613 9235 1668 | lsotiriou |
| John Hester | Healthcare | 612 8224 2871 | jhester |
| Tanushree Jain | Healthcare | 612 8224 2849 | tnjain |
| Elyse Shapiro | Healthcare | 613 9235 1877 | eshapiro |
| Steven Anastasiou | Industrials | 613 9235 1952 | sanastasiou |
| James Filius | Industrials | 613 9235 1612 | jfilius |
| Sam Haddad | Industrials | 612 8224 2819 | shaddad |
| Alex McLean | Industrials | 612 8224 2886 | amclean |
| Hamish Murray | Industrials | 613 9235 1813 | hmurray |
| Chris Savage | Industrials | 612 8224 2835 | csavage |
| Jonathan Snape | Industrials | 613 9235 1601 | jsnape |
| Damien Williamson | Industrials | 613 9235 1958 | dwilliamson |
| Peter Arden | Resources | 613 9235 1833 | parden |
| David Coates | Resources | 612 8224 2887 | dcoates |
| Stuart Howe | Resources | 613 9235 1856 | showe |
| Associate | | | |
| Joseph House | Associate Analyst | +61 3 9235 1624 | jhouse |

Bell Potter Securities Limited

ACN 25 006 390 7721
Level 29, 101 Collins Street
Melbourne, Victoria, 3000
Telephone +61 3 9256 8700
www.bellpotter.com.au

Bell Potter Securities (HK) Limited

Room 1701, 17/F
Prosperity Tower, 39 Queens Road
Central, Hong Kong, 0000
Telephone +852 3750 8400

Bell Potter Securities (US) LLC

Floor 39
444 Madison Avenue, New York
NY 10022, U.S.A
Telephone +1 917 819 1410

Bell Potter Securities (UK) Limited

16 Berkeley Street
London, England
W1J 8DZ, United Kingdom
Telephone +44 7734 2929

The following may affect your legal rights. Important Disclaimer:

This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. **In Hong Kong**, this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. **In the United States**, this research is issued and distributed by Bell Potter Securities (US) LLC which is a registered broker-dealer and member of FINRA. Any person receiving this report from Bell Potter Securities (US) LLC and wishing to transact in any security described herein should do so with Bell Potter Securities (US) LLC. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded, Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person.

Research Policies: For Bell Potter's Research Coverage Decision Making Process and Research Independence Policy, please refer to our company website:

<https://bellpotter.com.au/research-independence-policy/>

Disclosure of interest: Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document.

John Hester owns 5,000 shares in KZA.

Disclosure: Bell Potter Securities acted as lead manager of the company's capital raise for \$4m in October 2019 and \$9m in March 2020 April and received fees for that service.

Biotechnology Risk Warning:

The fact that the intellectual property base of a typical biotechnology company lies in science not generally regarded as accessible to the layman adds further to the riskiness with which biotechnology investments ought to be regarded. Clinical and regulatory risks are inherent in biotechnology stocks. Biotechnology developers usually seek US FDA approval for their technology which is a long and arduous three phase process to prove the safety, effectiveness and appropriate application or use of the developed drug and even after approval a drug can be the subject of an FDA investigation of subsequently discovered possible links between the drug and other diseases not previously diagnosed. Furthermore, the Australian exchange listed biotechnology sector is subject to influence by the global biotechnology sector, particularly that in the USA. Consequently, Australian exchange listed biotechnology stocks can experience sharp movements, both upwards and downwards, in both valuations and share prices, as a result of a re-rating of the sector both globally and in the USA, in particular. Investors are advised to be cognisant of these risks before buying such a stock.

ANALYST CERTIFICATION: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.